Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Onshore Yuan Breaks 6.9 Against U.S. Dollar as Trade War Intensifies
China Unicom Steps Up Mixed-Ownership Reform in Yunnan
Regulator Finds Kangmei Pharma Fabricated Financial Reports
LATEST
E-Commerce Newcomer Pinduoduo Beats Market Expectations in First Quarter
Ni Hao, Alexa: China Passes U.S. to Become World’s Largest Smart-Speaker Market
Central Bank to Unify Benchmark, Market-Based Lending Rates
JP Morgan Banker Offered Job to Kerry Logistics Scion in Bribery Case
Swiss Drone Makers Eye Chinese Market
Solar Energy Firm Hanergy to Delist From Hong Kong
Beingmate Gets Off Delisting Watchlist — But Has It Really Turned a Corner?
In Depth: Xiangshui Chemical Factory’s Recipe for Disaster
China Unicom Steps Up Mixed-Ownership Reform in Yunnan
Regulator Finds Kangmei Pharma Fabricated Financial Reports
Onshore Yuan Breaks 6.9 Against U.S. Dollar as Trade War Intensifies
Stricter Vehicle Emission Standards May Spell Further Bad News for Hobbled Industry
China Gives Tech SOEs Deadline for Improving Employee Incentives
Home Prices Rise in Major Chinese Cities
Taiwan Lawmakers Approve Same-Sex Marriage Bill
Former JP Morgan Banker Charged With Bribery in Hong Kong
Legendary Architect I.M. Pei Dies at 102
Clock Ticks Down to Starbucks Challenger Luckin’s New York Trading Debut
China Regulates Deposit Abuse in Sharing Economy
Don’t Overestimate Swine Fever Impact on 2019 Inflation, NDRC Says
Biotech Firm Viva to Raise Up to HK$1.5 Billion in Hong Kong IPO

By Liu Yanfei and Han Wei / Apr 26, 2019 02:56 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Another China-based biotech company will debut on the Hong Kong market.

Leading contract drug researcher Viva Biotech Holdings started its initial public offering share sales in Hong Kong Thursday aiming to raise between HK$1.18 billion and HK$1.52 billion ($150 million to $194 million).

Shanghai-based Viva planned to sell 345 million shares at a price range between HK$3.42 and HK$4.41 a share. The offering opened at 9 a.m. Thursday and will close at noon Tuesday in Hong Kong.

Established in 2008, Viva provides structure-based drug-discovery services to biotechnology and pharmaceutical customers. Its clients include nine of the world’s top 10 pharmaceutical companies, according to Viva’s prospectus. In 2018, Viva said it booked 210 million yuan ($31 million) of revenue, up 41.7% from the previous year, and 90.6 million yuan of net profit, up 18.7%.

Three cornerstone investors — Sinopharm Capital and two funds controlled by Shenzhen GTJA Investment Group ― subscribed for a combined 26% of Viva’s offering.

Viva’s stock will debut on the Hong Kong exchange May 9. China International Capital Corp. Hong Kong Securities Ltd. is the sole sponsor of the offering.

Related: Hong Kong Smiles on Biotech, Lowballs Club Med in Latest IPOs

Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.